Clinical Trial Update: Factor IX as Adjunctive Therapy to Emicizumab (EMIX) [EARLY_Phase 1]

View source ↗

Summary

This is an early Phase 1 study evaluating Factor IX as adjunctive therapy to Emicizumab (EMIX) for Hemophilia A. The trial status shows completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Factor IX (coagulation factor IX)
• Hemlibra (emicizumab)

Snippet

Sponsor: Tulane University | Conditions: Hemophilia A | EARLY_Phase 1 | Status: COMPLETED